Skip to main content
. Author manuscript; available in PMC: 2017 Sep 7.
Published in final edited form as: Leukemia. 2017 Feb 2;31(9):1951–1961. doi: 10.1038/leu.2016.393

Figure 7. Treatment with ARV-825 depletes BRD4 and its target proteins as well as induces apoptosis of sAML cells resistant to ruxolitinib.

Figure 7

A. HEL92.1.7 parental, HEL ruxolitinib-tolerant persister (HEL/Rux Persister) or ruxolitinib resistant (HEL/Rux Resistant) cells were treated with the indicated concentrations of ARV-825 for 48 hours. At the end of treatment, cells were stained with annexin V and TO-PRO-3 iodide and the % annexin V-positive, apoptotic cells was determined by flow cytometry. Columns, mean of three experiments; Bars, standard error of the mean. B. HEL92.1.7, HEL/ Rux Persister and HEL/Rux Resistant cells were treated with 500 nM of ARV-825 for 18 hours. Following this, cells were harvested and immunoblot analyses were conducted as indicated. The expression levels of β-Actin in the cell lysates served as the loading control.